SignaBlok’s TREM-1 nanotherapy accepted by the Nanotechnology Characterization Laboratory (NCL, Frederick, Maryland) into its Assay Cascade characterization and testing program as one of the most promising cancer nanomedicine candidates.

SignaBlok > News

SignaBlok > News

SignaBlok’s TREM-1 nanotherapy accepted by the Nanotechnology Characterization Laboratory (NCL, Frederick, Maryland) into its Assay Cascade characterization and testing program as one of the most promising cancer nanomedicine candidates.

SignaBlok awarded NIAMS / NIH SBIR Phase I grant to test new approach to treatment of scleroderma

SignaBlok awarded NIAMS / NIH SBIR Fast-Track grant to develop first-in-class TREM-1 inhibitor for treatment of rheumatoid arthritis

SCHOOL of nature: ligand-independent immunomodulatory peptides

Sigalov AB. Drug Discovery Today. 2020

SignaBlok awarded DoD SBIR Phase I contract to support new technology to prevent the effects of acute radiation syndrome

SignaBlok attended the COVID-19 Virtual Partnering event and presented company’s approach to treatment of acute respiratory distress syndrome (ARDS), a major complication in severe cases of COVID-19

Inhibition of Triggering Receptor Expressed on Myeloid Cells 1 Ameliorates Inflammation and Macrophage and Neutrophil Activation in Alcoholic Liver Disease in Mice

Tornai D, Furi I et al. Hepatol Commun. 2019

SignaBlok pitched on company’s standalone and combination immuno-oncology therapy at the 2019 Life Sciences Summit

SignaBlok wins NCI / NIH SBIR Phase II grant to test first-in-class TREM-1 inhibitor in combination with chemo- and immunotherapy for treatment of pancreatic cancer

SignaBlok selected as a RESI Pitch Challenge finalist to pitch on company’s oncology program at the 2019 Redefining Early Stage Investments (RESI) Conference